Visiongain Report Looks at Opportunities Within the $23bn Cell Therapy Technologies Market
Autolus Therapeutics plc - American Depositary Shares (AUTL)
Last autolus therapeutics plc - american depositary shares earnings: 11/7 07:06 am
Check Earnings Report
US:NASDAQ Investor Relations:
autolus.com/investor-relations
Company Research
Source: PR Newswire
LONDON, March 25, 2020 /PRNewswire/ -- Consumables, Equipment, System & Software, Cell Processing, Cell Processing Equipment, Single Use Equipment, Cell Preservation, Distribution, Handling, Process Monitoring & Quality Control, Human Cells, Animal Cells, Life Sciences & Research Companies, Research InstitutesVisiongain estimates that the global cell therapy technologies market will grow at a CAGR of 15% in the first half of the forecast period. In 2020, North America is estimated to hold 38% of the global cell therapy technologies market.How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new 201-page report you will receive 104 tables and 110 figures– all unavailable elsewhere.The 201-page Visiongain report provides clear detailed insight into the cell therapy technologies market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand-new report today y
Show less
Read more
Impact Snapshot
Event Time:
AUTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUTL alerts
High impacting Autolus Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AUTL
News
- Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsightPR Newswire
- Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsightPR Newswire
- Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.MarketBeat
- Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.MarketBeat
AUTL
Earnings
- 11/12/24 - Miss
AUTL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form S-8
- 11/14/24 - Form SC
- AUTL's page on the SEC website